Published in Br J Cancer on April 05, 2011
Prediction of breast cancer risk based on profiling with common genetic variants. J Natl Cancer Inst (2015) 2.54
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev (2015) 1.95
Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med (2013) 1.91
Public health implications from COGS and potential for risk stratification and screening. Nat Genet (2013) 1.79
A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol (2014) 1.48
Breast cancer risk prediction and individualised screening based on common genetic variation and breast density measurement. Breast Cancer Res (2012) 1.47
Life insurance: genomic stratification and risk classification. Eur J Hum Genet (2013) 1.39
The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol (2013) 1.39
Common genetic variants in prostate cancer risk prediction--results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev (2012) 1.29
End of the Beginning and Public Health Pharmacogenomics: Knowledge in 'Mode 2' and P5 Medicine. Curr Pharmacogenomics Person Med (2012) 1.23
Potential usefulness of single nucleotide polymorphisms to identify persons at high cancer risk: an evaluation of seven common cancers. J Clin Oncol (2012) 1.15
Prediction of breast cancer risk by genetic risk factors, overall and by hormone receptor status. J Med Genet (2012) 1.13
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Med (2015) 1.01
Can the breast screening appointment be used to provide risk assessment and prevention advice? Breast Cancer Res (2015) 1.01
Hereditary breast cancer: ever more pieces to the polygenic puzzle. Hered Cancer Clin Pract (2013) 0.99
Genetic architecture of colorectal cancer. Gut (2015) 0.97
Personalized screening for cancers: should we consider polygenic profiling? Per Med (2013) 0.94
Breast cancer screening: time to target women at risk. Br J Cancer (2013) 0.89
Public health genomics and personalized prevention: lessons from the COGS project. J Intern Med (2013) 0.89
Twenty-five years of breast cancer risk models and their applications. J Natl Cancer Inst (2015) 0.86
Population-based screening in the era of genomics. Per Med (2012) 0.84
Emerging putative biomarkers: the role of alpha 2 and 6 integrins in susceptibility, treatment, and prognosis. Prostate Cancer (2012) 0.83
The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making. Biomed Res Int (2014) 0.83
Implementing risk-stratified screening for common cancers: a review of potential ethical, legal and social issues. J Public Health (Oxf) (2013) 0.82
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. Br J Cancer (2015) 0.82
Breast cancer risk prediction and mammography biopsy decisions: a model-based study. Am J Prev Med (2013) 0.81
Why Breast Cancer Risk by the Numbers Is Not Enough: Evaluation of a Decision Aid in Multi-Ethnic, Low-Numerate Women. J Med Internet Res (2015) 0.80
Comparing Mammography Abnormality Features to Genetic Variants in the Prediction of Breast Cancer in Women Recommended for Breast Biopsy. Acad Radiol (2015) 0.80
Targeted Cancer Screening in Average-Risk Individuals. Am J Prev Med (2015) 0.79
Modeling the prevention of colorectal cancer from the combined impact of host and behavioral risk factors. Genet Med (2016) 0.79
An epidemiological perspective of personalized medicine: the Estonian experience. J Intern Med (2015) 0.78
Additive interactions between susceptibility single-nucleotide polymorphisms identified in genome-wide association studies and breast cancer risk factors in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol (2014) 0.78
Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev (2016) 0.78
Recommendations on breast cancer screening and prevention in the context of implementing risk stratification: impending changes to current policies. Curr Oncol (2016) 0.77
Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. Breast (2015) 0.77
No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol (2015) 0.77
Implementation of genome-wide complex trait analysis to quantify the heritability in multiple myeloma. Sci Rep (2015) 0.77
Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments. Cancer Gene Ther (2014) 0.77
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. J Clin Oncol (2017) 0.76
Estimating the effect of targeted screening strategies: an application to colonoscopy and colorectal cancer. Epidemiology (2017) 0.76
Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling? J Pers Med (2015) 0.75
Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. Per Med (2016) 0.75
Molecular genetics of breast and ovarian cancer: recent advances and clinical implications. Balkan J Med Genet (2012) 0.75
Constructing Hypothetical Risk Data from the Area under the ROC Curve: Modelling Distributions of Polygenic Risk. PLoS One (2016) 0.75
Genetic control of ductal morphology, estrogen-induced ductal growth, and gene expression in female mouse mammary gland. Endocrinology (2014) 0.75
Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda. J Gen Intern Med (2016) 0.75
Comparison of the efficiency of colorectal cancer screening programs based on age and genetic risk for reduction of colorectal cancer mortality. Eur J Hum Genet (2017) 0.75
"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. Fam Cancer (2014) 0.75
Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers. Front Genet (2017) 0.75
Is mammography screening history a predictor of future breast cancer risk? Eur J Epidemiol (2014) 0.75
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet (2008) 15.43
Cumulative association of five genetic variants with prostate cancer. N Engl J Med (2008) 15.34
A common variant associated with prostate cancer in European and African populations. Nat Genet (2006) 13.47
Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65
Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2007) 10.81
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet (2002) 8.89
Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1. Nat Genet (2009) 8.44
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06
Absolute numbers of lives saved and overdiagnosis in breast cancer screening, from a randomized trial and from the Breast Screening Programme in England. J Med Screen (2010) 4.72
Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst (2008) 4.52
Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res (2007) 3.97
Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet (2009) 3.94
Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet (2008) 3.14
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer Inst (2009) 2.88
FGFR2 variants and breast cancer risk: fine-scale mapping using African American studies and analysis of chromatin conformation. Hum Mol Genet (2009) 2.62
Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen (2004) 2.62
Breast cancer in young women: poor survival despite intensive treatment. PLoS One (2009) 2.36
Age-conditional probabilities of developing cancer. Stat Med (2003) 2.03
Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer (2009) 1.89
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease. Clin Cancer Res (2008) 1.74
Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol Biomarkers Prev (2010) 1.69
Genome-wide association studies in cancer--current and future directions. Carcinogenesis (2009) 1.39
Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. Br J Cancer (2009) 1.36
Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta (2010) 1.13
[Detection of cancer, sensitivity of the test and sensitivity of the screening program]. Rev Epidemiol Sante Publique (1998) 1.12
Maximising benefit and minimising harm of screening. BMJ (2008) 1.08
A tiny step closer to personalized risk prediction for breast cancer. N Engl J Med (2010) 1.01
Screening younger women with a family history of breast cancer--does early detection improve outcome? Eur J Cancer (2006) 0.94
Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract (2002) 0.92
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet (1994) 9.60
Tracking neuronal fiber pathways in the living human brain. Proc Natl Acad Sci U S A (1999) 9.19
Survival of patients with breast cancer attending Bristol Cancer Help Centre. Lancet (1990) 7.04
Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst (1999) 6.48
Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst (1994) 6.27
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet (2005) 6.18
Beyond randomized controlled trials: organized mammographic screening substantially reduces breast carcinoma mortality. Cancer (2001) 6.16
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet (1998) 5.35
The Swedish two county trial of mammographic screening for breast cancer: recent results and calculation of benefit. J Epidemiol Community Health (1989) 5.20
Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer (1997) 4.47
Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am (1992) 4.34
A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer (2002) 4.18
The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer (2004) 4.06
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
Breast cancer treatment and natural history: new insights from results of screening. Lancet (1992) 3.77
A novel method for prediction of long-term outcome of women with T1a, T1b, and 10-14 mm invasive breast cancers: a prospective study. Lancet (2000) 3.76
Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet (1995) 3.71
The natural history of breast carcinoma: what have we learned from screening? Cancer (1999) 3.55
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Dietary effects on breast-cancer risk in Singapore. Lancet (1991) 3.32
Efficacy of breast cancer screening by age. New results from the Swedish Two-County Trial. Cancer (1995) 3.32
Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study. Cancer Epidemiol Biomarkers Prev (1999) 3.29
The Swedish Two-County Trial twenty years later. Updated mortality results and new insights from long-term follow-up. Radiol Clin North Am (2000) 3.18
The LLP risk model: an individual risk prediction model for lung cancer. Br J Cancer (2007) 3.15
Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nat Genet (1992) 3.13
How many more breast cancer predisposition genes are there? Breast Cancer Res (1999) 3.10
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene (2006) 3.09
Fetal loss, gravidity, and pregnancy order. Early Hum Dev (1978) 3.06
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet (1994) 3.05
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast (2008) 2.96
Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene (1995) 2.91
Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology (2001) 2.89
Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India. J Bacteriol (2000) 2.81
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet (1985) 2.76
The Gothenburg breast screening trial: first results on mortality, incidence, and mode of detection for women ages 39-49 years at randomization. Cancer (1997) 2.75
Risk models for familial ovarian and breast cancer. Genet Epidemiol (2000) 2.75
A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol (2000) 2.73
Models of genetic susceptibility to breast cancer. Oncogene (2006) 2.69
Complex patterns of ETS gene alteration arise during cancer development in the human prostate. Oncogene (2007) 2.68
Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci (2001) 2.64
Overdiagnosis in screening: is the increase in breast cancer incidence rates a cause for concern? J Med Screen (2004) 2.62
Age at first birth, parity and risk of breast cancer: a meta-analysis of 8 studies from the Nordic countries. Int J Cancer (1990) 2.61
Control of tuberculosis by community health workers in Bangladesh. Lancet (1997) 2.55
Factors affecting morbidity and mortality after surgery for obstructive jaundice: a review of 373 patients. Gut (1983) 2.53
Early onset of breast cancer in a group of British black women. Br J Cancer (2008) 2.47
High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients. Cancer Res (1996) 2.43
A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (1999) 2.39
Family history of breast cancer: what do women understand and recall about their genetic risk? J Med Genet (1998) 2.27
Quantifying the potential problem of overdiagnosis of ductal carcinoma in situ in breast cancer screening. Eur J Cancer (2003) 2.26
Localization to Xq27 of a susceptibility gene for testicular germ-cell tumours. Nat Genet (2000) 2.26
Screening for prostate cancer in the UK. Seems to be creeping in by the back door. BMJ (2001) 2.22
Familial cancer syndromes. Lancet (1994) 2.16
A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature (1987) 2.15
Ambulatory urodynamics. Br J Urol (1996) 2.06
ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet (1998) 2.06
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology (2006) 1.98
Infiltrating lobular carcinoma of the breast. Histopathology (1982) 1.98
Blood flow changes in human somatosensory cortex during anticipated stimulation. Nature (1995) 1.96
Randomised controlled trial of educational package on management of menorrhagia in primary care: the Anglia menorrhagia education study. BMJ (1999) 1.96
Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling. Br J Cancer (1996) 1.93
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br J Cancer (2011) 1.86
Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer (2013) 1.85
MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. Oncogene (2003) 1.83
A case-control study to estimate the impact on breast cancer death of the breast screening programme in Wales. J Med Screen (2004) 1.81
The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer. Br J Cancer (1999) 1.80
Diffusion tensor imaging reveals white matter reorganization in early blind humans. Cereb Cortex (2005) 1.80
A case-control study to estimate the impact of the Icelandic population-based mammography screening program on breast cancer death. Acta Radiol (2007) 1.80
A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet (2000) 1.80
Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer (2010) 1.79
Detection method, tumour size and node metastases in breast cancers diagnosed during a trial of breast cancer screening. Eur J Cancer Clin Oncol (1987) 1.79
Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet (1996) 1.79
The genetics of breast and ovarian cancer. Br J Cancer (1995) 1.78
The management of men with acute urinary retention. National Prostatectomy Audit Steering Group. Br J Urol (1998) 1.76
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol (2011) 1.73
Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis. Dement Geriatr Cogn Disord (1999) 1.73
Familial site-specific ovarian cancer is linked to BRCA1 on 17q12-21. Am J Hum Genet (1994) 1.71
Retrospective and prospective multi-institutional laparoscopic cholecystectomy study organized by the Society of American Gastrointestinal Endoscopic Surgeons. Surg Endosc (1992) 1.71
A systematic review and meta-analysis of family history and risk of ovarian cancer. Br J Obstet Gynaecol (1998) 1.70
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst (2000) 1.69
Effect of breast cancer screening after age 65. J Med Screen (1995) 1.69
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med (1996) 1.68
Presymptomatic screening for multiple endocrine neoplasia type 2A with linked DNA markers. The MEN 2A International Collaborative Group. Lancet (1991) 1.68
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer (2005) 1.68
Tip60 is a nuclear hormone receptor coactivator. J Biol Chem (1999) 1.67
Written consent about sexual function in men undergoing transurethral prostatectomy. Br J Urol (1994) 1.65
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer (2008) 1.62
UK Lung Screen (UKLS) nodule management protocol: modelling of a single screen randomised controlled trial of low-dose CT screening for lung cancer. Thorax (2011) 1.62
Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. Br J Cancer (2011) 1.62
Basal cells are progenitors of luminal cells in primary cultures of differentiating human prostatic epithelium. Prostate (1998) 1.61
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int (2010) 1.60
Multi-state Markov models in cancer screening evaluation: a brief review and case study. Stat Methods Med Res (2010) 1.60